Call for Abstract
Scientific Program
-
University of Montreal, Canada
University of Washington, USA
Tanzania Vaccine Institute, Tanzania
Alexandria University, Egypt
Lanzhou Veterinary Research Institute, China
Sassari University School of Medicine, Italy
The University of Melbourne, Australia
Technical University of Braunschweig, Germany
Tsukuba Primate Research Center, Japan
Vaccines and Sera Torlak, Serbia
Emory University, USA
Faculdade de Medicina Santo, Brazil
Centro de Ingenieria Genetica y Biotecnologia, Cuba
University of KwaZulu-Natal, Belgium
National Health Research Institute, Taiwan
Korea University, Korea
Center for Genetic Engineering and Biotechnology, Cuba
Indonesian Technical Advisory Committee on Immunization, Indonesia
Walter Reed Army Institute of Research, USA
USAMRIID, USA
Karolinska Institutet, Sweden
Gulu University, Uganda
The Royal Children’s Hospital, Australia
University of Groningen, Netherlands
Central Institute for Research on Goats, India
INSERM, France
University of Sarajevo, Bosnia and Herzegovina
University of British Columbia, Canada
Temple University Center for Biotechnology, USA
UC Davis School of Medicine, USA
The Scripps Research Institute, USA
The University of Tokyo, Japan
Texas Biomedical Research Institute, USA
Flinders University, Australia
The George Washington University, USA
The University of Adelaide, South Australia
University of Michigan Medical School, USA
University of Louisville, USA
National Centre for Biotechnology, Spain
Pontifical Universtity of Salamanca, Spain
Universidade Federal de Goias, Brazil
JJ Strossmayer University, Croatia
Tehran University of Medical Sciences, Iran
Medical University of Vienna, Austria
University of Bedfordshire, UK
University of Oxford, UK
The Tazuke Kofukai Medical Research Institute, Japan
Pasteur Institute of Iran, Iran
Palacky University, Czech Republic
The University of Western Ontario, Canada
Chonbuk National University, South Korea
-
Liquidia Technologies Inc., USA
Profectus BioSciences, Inc., USA
Prokarium Ltd., UK
FluGen Inc., USA
Novartis Vaccines, USA
Merck & Co., Inc., USA
Arbovax Inc., USA
Merck Millipore, Europe
Sanofi Pasteur, USA
UNIVAC llc, Belgium
Bavarian Nordic, Germany
VALNEVA, Austria
Cellular Technology Limited, USA
Celldex Therapeutics, USA
Serum Institute of India, India
Vedantra Pharmaceuticals, USA
Shanghai Zerun Biotechnology Co .,Ltd. China
GenPhar Inc., USA
InnaVirVax, USA
West Pharmaceutical Services, USA
Inovio Pharmaceuticals, USA
VaxInnate Corporation, USA
Vaxart, Inc., USA
Iliad Biotechnologies, Scotland
European Institute of Innovation and Technology, Europe
REIMS, France
International Vaccine Institute, Korea
Micronutrient Initiative, Bangladesh
Slovak Academy of Sciences, Solvakia
5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, will be organized around the theme “Vaccine Research: From Bench to Bedside”
Vaccines Asia Pacific-2015 is comprised of 22 tracks and 121 sessions designed to offer comprehensive sessions that address current issues in Vaccines Asia Pacific-2015.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 2-1HIV vaccine
- Track 2-2Ebola vaccine
- Track 2-3Cancer vaccination
- Track 2-4Vaccine for severe acute respiratory syndrome
- Track 2-5Need of vaccination for major diseases
- Track 2-6Others
- Track 3-1Recent trends in vaccines development path
- Track 3-2Current technologies using in vaccines discovery
- Track 3-3New vaccines against infectious diseases
- Track 3-4Recent technologies in modifying bacterial genome
- Track 4-1Progress and challenges
- Track 4-2Others
- Track 5-1Whooping cough Vaccines in pregnant women
- Track 5-2Immunization before pregnancy
- Track 5-3Immunization during pregnancy
- Track 5-4Consequences of halting vaccination in pregnancy
- Track 5-5Chiropractic vaccination care in women and pregnancy
- Track 5-6Others
- Track 6-1Business Development of Animal Vaccines
- Track 6-2Business Development of Human Vaccines
- Track 6-3Challenges and Innovation
- Track 6-4Phyto vaccines
- Track 6-5Planning
- Track 7-1Safety considerations in vaccination
- Track 7-2Vaccines and vaccination knowledge
- Track 7-3Health care outcomes of different aged people vaccinated
- Track 7-4Safety and efficacy of vaccines
- Track 7-5Vaccines and vaccination- health care improvement.
- Track 7-6Others
- Track 8-1Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
- Track 8-2Diphtheria and tetanus toxoids usage in pediatrics
- Track 8-3Administration and routes of administration of toxoids
- Track 8-4Innovative toxoid vaccine development
- Track 8-5Maternal immunization
- Track 8-6Others
- Track 9-1Yellow fever: Epidemiology and prevention
- Track 9-2Typhoid fever vaccination
- Track 9-3Advantage of live attenuated vaccines
- Track 9-4Risk factors in unsing live attenuated vaccines
- Track 9-5Tubercular vaccination
- Track 9-6Cancer Therapeutic Vaccination
- Track 9-7Others
- Track 10-1Animal diseases and vaccination
- Track 10-2Animal health outcomes
- Track 10-3Bovine vaccine technology
- Track 10-4Current status of veterinary vaccines
- Track 10-5Others
- Track 10-6Pet vaccines and vaccination
- Track 11-1Hepatitis B virus spread and control
- Track 11-2Others
- Track 11-3Recombinant technology usage
- Track 11-4Role of nanotechnology in vaccine delivery
- Track 11-5Vaccines and its target compositions
- Track 11-6Virus-like particles as vaccines, vectors and adjutants
- Track 12-1Designing of adjutvants
- Track 12-2Rationale selection of adjuvants
- Track 12-3Skin delivery techniques
- Track 12-4Adjuvant interactions
- Track 12-5BeneficialAdjuvents
- Track 12-6Others
- Track 13-1Major discoveries in carbohydrate based vaccines
- Track 13-2Glycomics- Vaccine Discoveries
- Track 13-3Identification, synthesis and evaluation of unique glycan epitopes
- Track 13-4Targeting the surface carbohydrates of infectious agents
- Track 13-5Role of carbohydrate-based vaccines in cancer therapy
- Track 13-6Others
- Track 14-1Mucosal Vaccines Delivery
- Track 14-2Mucosal Vaccines Design
- Track 14-3Others
- Track 15-1Dendritic cell based vaccines and development
- Track 15-2Recombinent vector based immunization
- Track 15-3DNA Vaccination
- Track 15-4T-cell receptor peptide vaccines
- Track 15-5Targeted bacterial protein identification
- Track 15-6Others
- Track 16-1Immunization and its side effects in geriatrics
- Track 16-2Vaccine dosing and administration in older adults
- Track 16-3Herpes zoster vaccine
- Track 16-4Pneumococcal polysaccharide vaccine
- Track 16-5Contraindications and precautions during vaccination in geriatrics
- Track 16-6Risk factors in geriatric immunization
- Track 16-7Others
- Track 17-1New approaches to combat bacterial pathogens
- Track 17-2Public health concerns in vaccination
- Track 17-3Contraindications of vaccinations
- Track 17-4Vaccines formulation and technologies used in conjugated vaccines
- Track 17-5Vaccine resistance and need of Next-Gen Conjugate Vaccines
- Track 17-6Others
- Track 18-1Others
- Track 18-2Peptide Based vaccines
- Track 18-3Protein based vaccines
- Track 19-1Conjugated vaccine discovery and translation of new vaccine technology
- Track 19-2Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
- Track 19-3Manufacturing of Conjugate Vaccines
- Track 19-4Others
- Track 19-5Production of Conjugate Vaccines Using Recombinant DNA Technology
- Track 19-6Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants
- Track 20-1Chickenpox vaccines
- Track 20-2Diphtheria vaccines
- Track 20-3Polio vaccines
- Track 20-4Hib Vaccines
- Track 20-5Hepatitis A vaccines
- Track 20-6Hepatitis B vaccines
- Track 20-7Flu vaccines
- Track 20-8Measles vaccines
- Track 20-9Mumps vaccines
- Track 20-10Pertussis vaccines
- Track 20-11Pneumococcal vaccines
- Track 20-12Rotavirus vaccines
- Track 20-13Rubella vaccines
- Track 20-14Tetanus vaccines
- Track 20-15Others
- Track 21-1Cancer Therapeutic Vaccines
- Track 21-2Vaccines for Preventive cancer
- Track 21-3Others
- Track 22-1Preclinical stage development and factors affecting
- Track 22-2Clinical stage process
- Track 22-3Vaccines efficacy testing
- Track 22-4Manufacture of the vaccine to Good Manufacturing Practice standards
- Track 22-5Complications and consequences affecting vaccine development
- Track 22-6Others
